OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:42:52 2024-06-27 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
2023	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI

Alpha Holdings Solicits Proxies from the Shareholders of OncoSec Medical

January 07, 2020 at 04:30 pm EST

On January 7, 2020, Alpha Holdings, Inc announced that it has sent a letter to OncoSec Medical Incorporated stockholders in advance of the Company’s upcoming special meeting of stockholders, currently scheduled for January 17, 2020, urging them to vote on its proxy card ‘against’ the proposed takeover of the Company by China Grand Pharmaceuticals and Healthcare Holdings and Sirtex Medical US Holdings, Inc.

Latest news about OncoSec Medical Incorporated

Motion for Asset Sale Approved for OncoSec Medical Incorporated	23-08-09	CI
Motion for Asset Sale Filed by OncoSec Medical Incorporated	23-07-28	CI
OncoSec Medical Incorporated(NasdaqCM:ONCS) dropped from S&P TMI Index	23-06-28	CI
Wall Street Set to Open Lower Ahead of June's Flash PMI; Oil Prices Drop Sharply	23-06-23	MT
US Futures Trend Lower Premarket Friday Ahead of June's Flash PMI	23-06-23	MT
Top Premarket Gainers	23-06-23	MT
OncoSec Medical Incorporated(OTCPK:ONCS.Q) dropped from NASDAQ Composite Index	23-06-23	CI
Certain Stock Options of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Common Stock of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Promissory Notes of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Warrants of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
OncoSec Medical Incorporated Announces Resignation of Dr. Robert Arch as Chief Executive Officer	23-06-14	CI
OncoSec Medical Incorporated Announces Management Resignations	23-06-14	CI
OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer	23-06-14	CI
OncoSec Medical Incorporated Filed for Bankruptcy	23-06-14	CI
OncoSec Medical Closes $1.3 Million Registered Direct Offering	23-05-19	MT
Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program	23-05-16	CI
OncoSec Medical Launches $2 Million Registered Direct Offering; Shares Surge	23-04-10	MT
Sector Update: Health Care Stocks Higher Late Monday	23-04-03	MT
Top Midday Decliners	23-04-03	MT
Surging Oil Prices Trigger Fresh Inflation Worries, Driving Mixed Premarket Trading for US Equity Futures	23-04-03	MT
Top Premarket Decliners	23-04-03	MT
OncoSec Medical Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma Refractory to Anti-PD-1 Treatment	23-04-03	CI
Top Premarket Decliners	23-03-28	MT
OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-14	CI

Chart OncoSec Medical Incorporated

Duration

Period

More charts

Company Profile

OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.

Sector

Biotechnology & Medical Research

Calendar

2025-03-11 - Q2 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOSEC MEDICAL INCORPORATED	-.--%	596
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research

OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Biotechnology & Medical Research

Alpha Holdings Solicits Proxies from the Shareholders of OncoSec Medical

Latest news about OncoSec Medical Incorporated

Chart OncoSec Medical Incorporated

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research